NCT07834398CompletedPhase 3
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
Evaluating the Efficacy of Various Weekly GLP1receptor Agonist Among Obese Individuals Without Diabetes
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (actual)
- First submitted
- 5 Aug 2026
- Start date
- 14 Nov 2025
- Primary completion date
- 13 Apr 2026
- Lead sponsor
- Zagazig University
- Diseases
- Obesity
- NCT number
- NCT07834398
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 150
- From 14 Nov 2025 to the primary completion date, 13 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with liver disease, renal dysfunction diabetes, pancreatic diseases ,thyroid disorder or goiter psychological diseases like depression and pregnant women, and Patients who will refuse
Who the study is looking for
- Subjects (above 18 years old) obese body mass index (BMI) above 30
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New Najran General Hospital Coordinator of this site? Confirm its status | Najran | Saudi Arabia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.